RVNC

Revance Therapeutics, Inc. [RVNC] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

RVNC Stock Summary

Top 10 Correlated ETFs

RVNC


Top 10 Correlated Stocks

RVNC


In the News

05:51 29 Sep 2023 RVNC

Revance Therapeutics: Impressive Sales Growth/Concerning Cash Burn

Revance Therapeutics, Inc. stock has fallen by half in the past six months, despite impressive sales growth, prompting speculation on whether it is now a good buy. The recent DAXXIFY launch seems to be proceeding well, but quarterly cash burn remains an issue as Revance challenges Botox in this space. Analysts have mixed opinions on the stock, with some reiterating buy ratings and others issuing neutral ratings.

02:27 29 Sep 2023 RVNC

3 Healthcare Stocks to Sell in September Before They Crash & Burn

The healthcare industry comprises multiple sectors, including biotechnology, pharmaceuticals, and healthcare equipment, each offering a unique and potentially risky opportunity. News regarding FDA approval and positive results for therapies, pharmaceuticals, and trials greatly influences the outlook for companies, especially ones with small market cap share price.

12:43 29 Sep 2023 RVNC

3 Very Oversold Biotech Stocks to Buy Right Now

After I spent many years following Wall Street, there are a few characteristics about the “big money”  that stand out for me. One of these traits is that many if not most large investors are very reluctant to buy stocks that have a 60%-80% chance of climbing a great deal in the long term but a 10%-15% chance of plunging in the short-to-medium term.

08:53 29 Sep 2023 RVNC

Revance shares gain 8% after FDA approval of cervical dystonia treatment

Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dystonia in adults. Cervical dystonia is a chronic disease that causes painful, involuntary neck muscle contractions and affects about 60,000 people in the U.S. Daxxify, a Botox competitor, previously received FDA approval late last year for the temporary improvement of frown lines.

08:06 29 Sep 2023 RVNC

Revance's Botox rival gets FDA approval for painful neck muscle condition

The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Botox.

07:41 29 Sep 2023 RVNC

Revance Therapeutics, Inc. (RVNC) Reports Q2 Loss, Tops Revenue Estimates

Revance Therapeutics, Inc. (RVNC) came out with a quarterly loss of $0.80 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $0.88 per share a year ago.

11:08 29 Sep 2023 RVNC

After Plunging -17.93% in 4 Weeks, Here's Why the Trend Might Reverse for Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics, Inc. (RVNC) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

08:41 29 Sep 2023 RVNC

7 Healthcare Stocks to Make You the Millionaire Next Door

Investing in healthcare stocks can be a wise decision for those looking to become wealthy in the long term. Some of the best healthcare stocks to buy are firms that are developing highly effective drugs for prevalent diseases for which there are no real effective treatments.

02:16 29 Sep 2023 RVNC

This Botox Rival Has Investors Smiling With A 100% Gain This Year. The Stock Broke Out Today.

Revance Therapeutics, a biotech stock, is at a 52-week high and reports earnings Tuesday. Their frown line treatment lasts longer than Botox.

07:38 29 Sep 2023 RVNC

Top 4 Stocks Set to Beat on Earnings Today After Market Closes

We have narrowed our search to four stocks that are set to report earnings results today after market closes. These are: WYNN, CELH, RVNC and IAC.

RVNC Financial details

Company Rating
Buy
Market Cap
1.14B
Income
-362.61M
Revenue
186.4M
Book val./share
0.32
Cash/share
3.82
Dividend
-
Dividend %
-
Employees
534
Optionable
No
Shortable
Yes
Earnings
06 Nov 2023
P/E
-2.79
Forward P/E
-
PEG
-3.59
P/S
5.7
P/B
37.77
P/C
3.08
P/FCF
-4.53
Quick Ratio
4.55
Current Ratio
5.12
Debt / Equity
16.14
LT Debt / Equity
15.37
-
-
EPS (TTM)
-4.58
EPS next Y
-
EPS next Q
-1.67
EPS this Y
15.29%
EPS next Y
-
EPS next 5Y
6.11%
EPS last 5Y
4.46%
Revenue last 5Y
104.25%
Revenue Q/Q
17.84%
EPS Q/Q
-1.23%
-
-
-
-
SMA20
-27.78%
SMA50
-43.48%
SMA100
-61.76%
Inst Own
102.73%
Inst Trans
1.07%
ROA
-61%
ROE
-916%
ROC
-0.53%
Gross Margin
62%
Oper. Margin
-148%
Profit Margin
-195%
Payout
-
Shs Outstand
87.96M
Shs Float
75.28M
-
-
-
-
Target Price
32
52W Range
11.1-37.98
52W High
-68.24%
52W Low
+6.82%
RSI
25
Rel Volume
0.7
Avg Volume
1.74M
Volume
1.22M
Perf Week
-10.61%
Perf Month
-33.31%
Perf Quarter
-62.66%
Perf Half Y
-64.05%
-
-
-
-
Beta
0.800484
-
-
Volatility
0.38%, 2.34%
Prev Close
-2.81%
Price
11.75
Change
-5.39%

RVNC Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
0.10.010.261.151.82
Net income per share
-3.94-3.59-4.86-4.25-4.9
Operating cash flow per share
-2.88-2.44-3.08-3.28-2.66
Free cash flow per share
-3.08-2.52-3.15-3.55-2.98
Cash per share
4.866.687.523.334.69
Book value per share
4.035.196.451.010.17
Tangible book value per share
4.035.192.69-1.98-1.26
Share holders equity per share
4.035.196.451.010.17
Interest debt per share
0.40.683.924.95.98
Market cap
728.13M705.37M1.64B1.1B1.34B
Enterprise value
654.88M563.55M1.52B1.32B1.65B
P/E ratio
-5.11-4.52-5.83-3.84-3.77
Price to sales ratio
195.261.71K107.2714.1610.13
POCF ratio
-6.98-6.64-9.21-4.97-6.94
PFCF ratio
-6.54-6.45-9-4.6-6.2
P/B Ratio
53.134.3916.09106.53
PTB ratio
53.134.3916.09106.53
EV to sales
175.621.36K99.3516.9112.46
Enterprise value over EBITDA
-4.7-3.54-5.78-5.04-6.84
EV to operating cash flow
-6.28-5.31-8.53-5.94-8.53
EV to free cash flow
-5.88-5.15-8.33-5.49-7.63
Earnings yield
-0.2-0.22-0.17-0.26-0.27
Free cash flow yield
-0.15-0.16-0.11-0.22-0.16
Debt to equity
0.10.130.574.7433.21
Debt to assets
0.060.090.290.610.72
Net debt to EBITDA
0.530.890.46-0.82-1.28
Current ratio
6.57.247.383.664.95
Interest coverage
-3.24K0-18.03-43.79-16.52
Income quality
0.730.670.630.790.54
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
14.44150.159.770.360.03
Research and developement to revenue
24.81249.068.211.490.76
Intangibles to total assets
000.30.380.18
Capex to operating cash flow
0.070.030.020.080.12
Capex to revenue
-1.9-7.84-0.28-0.23-0.17
Capex to depreciation
-4.11-1.11-0.41-0.91-0.59
Stock based compensation to revenue
4.3643.392.380.560.39
Graham number
18.920.4826.579.854.37
ROIC
-0.91-0.57-0.44-0.64-0.58
Return on tangible assets
-0.63-0.46-0.56-0.87-0.75
Graham Net
3.194.031.64-3.41-2.9
Working capital
175.95M255.62M389.04M178.83M299.05M
Tangible asset value
145.62M225.49M155.98M-133.83M-91.58M
Net current asset value
127.2M181.81M104.07M-216.58M-194.57M
Invested capital
0.10.130.574.7433.21
Average receivables
13.52M13.5M914.5K2.59M7.34M
Average payables
7.62M8.22M10.33M11.63M7.57M
Average inventory
002.94M8.02M14.24M
Days sales outstanding
2.64K043.5615.7131.22
Days payables outstanding
00968.72165.3232.12
Days of inventory on hand
00449.73158.32129.46
Receivables turnover
0.1408.3823.2411.69
Payables turnover
000.382.2111.37
Inventory turnover
000.812.312.82
ROE
-0.98-0.69-0.75-4.19-28.29
Capex per share
-0.2-0.07-0.07-0.27-0.32

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
0.40.40.620.610.69
Net income per share
-0.88-1.17-1.8-0.81-0.8
Operating cash flow per share
-0.63-0.8-0.38-0.86-0.64
Free cash flow per share
-0.71-0.83-0.64-0.87-0.63
Cash per share
3.345.244.253.383.82
Book value per share
-0.042.020.16-0.330.32
Tangible book value per share
-2.81-0.61-1.14-1.66-0.94
Share holders equity per share
-0.042.020.16-0.330.32
Interest debt per share
6.36.025.275.435.22
Market cap
968.25M1.95B1.48B2.61B2.12B
Enterprise value
1.34B2.27B1.79B2.91B2.41B
P/E ratio
-3.94-5.75-2.56-9.89-7.87
Price to sales ratio
34.1367.1929.6352.9836.43
POCF ratio
-21.89-33.69-49.01-37.6-39.68
PFCF ratio
-19.51-32.61-28.85-37.14-39.88
P/B Ratio
-368.0213.38117.39-97.9879.07
PTB ratio
-368.0213.38117.39-97.9879.07
EV to sales
47.1178.3435.8359.0441.44
Enterprise value over EBITDA
-26.26-33.72-31.85-54.65-39.62
EV to operating cash flow
-30.22-39.28-59.26-41.9-45.13
EV to free cash flow
-26.93-38.02-34.89-41.39-45.36
Earnings yield
-0.06-0.04-0.1-0.03-0.03
Free cash flow yield
-0.05-0.03-0.03-0.03-0.03
Debt to equity
-166.362.9433.21-16.3416.14
Debt to assets
0.780.60.720.80.72
Net debt to EBITDA
-7.24-4.8-5.51-5.61-4.79
Current ratio
3.385.564.954.145.12
Interest coverage
-14.93-11.2-19.89-12.9-15
Income quality
0.720.680.211.160.79
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
1.652.231.821.291.31
Research and developement to revenue
0.880.90.390.470.39
Intangibles to total assets
0.350.270.180.20.18
Capex to operating cash flow
0.120.030.70.010
Capex to revenue
-0.19-0.07-0.42-0.020
Capex to depreciation
-0.82-0.22-1.15-0.130.08
Stock based compensation to revenue
0.330.620.210.270.27
Graham number
0.867.32.532.452.41
ROIC
-0.12-0.13-0.16-0.14-0.13
Return on tangible assets
-0.17-0.16-0.3-0.15-0.14
Graham Net
-4.56-2.35-2.63-3.39-2.64
Working capital
183.72M340.86M299.05M245.04M304.87M
Tangible asset value
-196.62M-44.12M-91.58M-135.07M-78.85M
Net current asset value
-303.57M-150.28M-194.57M-251.45M-191.8M
Invested capital
-166.362.9433.21-16.3416.14
Average receivables
5.03M8.66M11.54M13.36M16.21M
Average payables
11.65M7.01M2.65M8.77M10.67M
Average inventory
12.13M15.39M17.75M23.05M31.11M
Days sales outstanding
17.7336.3920.4428.0526.39
Days payables outstanding
125.436.2417.472.3335.25
Days of inventory on hand
128.5314470.14154.58145.51
Receivables turnover
5.072.474.43.213.41
Payables turnover
0.7214.435.171.242.55
Inventory turnover
0.70.621.280.580.62
ROE
23.37-0.58-11.472.48-2.51
Capex per share
-0.08-0.03-0.26-0.010

RVNC Frequently Asked Questions

What is Revance Therapeutics, Inc. stock symbol ?

Revance Therapeutics, Inc. is a US stock , located in Nashville of Tn and trading under the symbol RVNC

Is Revance Therapeutics, Inc. buy or a sell ?

4 stock analysts have 4 predictions with a medium analyst target price of $33.5. The lowest prediction is $24 and the highest is $38

What is RVNC stock prediction ?

With a median analyst target price of $35, 1 stock analysts have made 1 forecasts in last 90 days. $35 is the lowest and $35 is the greatest projection.

What is Revance Therapeutics, Inc. stock quote today ?

Revance Therapeutics, Inc. stock price is $11.75 today.

Is Revance Therapeutics, Inc. stock public?

Yes, Revance Therapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap